2024 U.S. Revenue Highlights

2024 U.S. Revenue Highlights

• Pfizer/BioNTech’s COVID-19 vaccine, Comirnaty, brought in $5.35 billion in U.S. sales for 2024 Reuters.

• Moderna’s COVID-19 vaccine, Spikevax, generated $1.8 billion in U.S. revenue in 2024 Reuters.

Combined, that’s approximately $7.15 billion in U.S. mRNA vaccine revenue for 2024.

---

Breakdown:

Vaccine	Company	U.S. Revenue (2024)
Comirnaty	Pfizer/BioNTech	$5.35 B
Spikevax	Moderna	$1.8 B
Total	—	$7.15 B